Physician profile
Rafael Torosyan
NPI 1578901625
$3,347.97
in general payments reported to CMS, 2019-2025
16 companies · $2,773 in 2025
The $2,773 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $143 · 2021: $109 · 2022: $78.99 · 2023: $56.61 · 2024: $25.70 · 2025: $2,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,700 · Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,700.00 |
| Food and Beverage | $155.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,724.08 | 2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $123.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $78.99 | 2022 | |
| Daiichi Sankyo INC. | $69.19 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $61.18 | 2020-2023 | Rayaldee |
| Vifor Pharma, INC. | $41.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $38.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.36 | 2021-2023 | |
| Scpharmaceuticals INC. | $26.50 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.70 | 2024 | Ultomiris |
| Genzyme Corporation | $25.22 | 2023 | |
| Horizon Therapeutics Plc | $23.72 | 2021 | |
| Novo Nordisk INC | $22.38 | 2025 | Ozempic |
| Akebia Therapeutics INC | $18.95 | 2019 | |
| Amgen INC. | $18.47 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $17.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Torosyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.